NERV
Price
$2.17
Change
+$0.17 (+8.50%)
Updated
Jul 24 closing price
Capitalization
13.99M
18 days until earnings call
ZLDPF
Price
$61.06
Change
+$2.66 (+4.55%)
Updated
Jul 24 closing price
Capitalization
4.12B
Interact to see
Advertisement

NERV vs ZLDPF

Header iconNERV vs ZLDPF Comparison
Open Charts NERV vs ZLDPFBanner chart's image
Minerva Neurosciences
Price$2.17
Change+$0.17 (+8.50%)
Volume$64.96K
Capitalization13.99M
Zealand Pharma A/S
Price$61.06
Change+$2.66 (+4.55%)
Volume$153
Capitalization4.12B
NERV vs ZLDPF Comparison Chart in %
Loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NERV vs. ZLDPF commentary
Jul 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a StrongBuy and ZLDPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2025
Stock price -- (NERV: $2.17 vs. ZLDPF: $61.06)
Brand notoriety: NERV and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NERV: 410% vs. ZLDPF: 23%
Market capitalization -- NERV: $13.99M vs. ZLDPF: $4.12B
NERV [@Biotechnology] is valued at $13.99M. ZLDPF’s [@Biotechnology] market capitalization is $4.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileZLDPF’s FA Score has 1 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • ZLDPF’s FA Score: 1 green, 4 red.
According to our system of comparison, both NERV and ZLDPF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NERV’s TA Score shows that 5 TA indicator(s) are bullish while ZLDPF’s TA Score has 5 bullish TA indicator(s).

  • NERV’s TA Score: 5 bullish, 4 bearish.
  • ZLDPF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ZLDPF is a better buy in the short-term than NERV.

Price Growth

NERV (@Biotechnology) experienced а +9.05% price change this week, while ZLDPF (@Biotechnology) price change was +9.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.05%. For the same industry, the average monthly price growth was +18.11%, and the average quarterly price growth was +28.55%.

Reported Earning Dates

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+6.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDPF($4.12B) has a higher market cap than NERV($14M). NERV YTD gains are higher at: -2.323 vs. ZLDPF (-40.352). NERV has higher annual earnings (EBITDA): 8.58M vs. ZLDPF (-1.13B). ZLDPF has more cash in the bank: 8.54B vs. NERV (17.3M). NERV has less debt than ZLDPF: NERV (0) vs ZLDPF (395M). ZLDPF has higher revenues than NERV: ZLDPF (55.7M) vs NERV (0).
NERVZLDPFNERV / ZLDPF
Capitalization14M4.12B0%
EBITDA8.58M-1.13B-1%
Gain YTD-2.323-40.3526%
P/E Ratio2.65N/A-
Revenue055.7M-
Total Cash17.3M8.54B0%
Total Debt0395M-
FUNDAMENTALS RATINGS
NERV vs ZLDPF: Fundamental Ratings
NERV
ZLDPF
OUTLOOK RATING
1..100
1219
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10077
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
5565
P/E GROWTH RATING
1..100
986
SEASONALITY SCORE
1..100
5016

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for ZLDPF (76) in the null industry. This means that NERV’s stock grew somewhat faster than ZLDPF’s over the last 12 months.

ZLDPF's Profit vs Risk Rating (77) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that ZLDPF’s stock grew similarly to NERV’s over the last 12 months.

ZLDPF's SMR Rating (94) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that ZLDPF’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (55) in the Biotechnology industry is in the same range as ZLDPF (65) in the null industry. This means that NERV’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (6) in the null industry is significantly better than the same rating for NERV (98) in the Biotechnology industry. This means that ZLDPF’s stock grew significantly faster than NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NERVZLDPF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
67%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
57%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
58%
Advances
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
71%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
66%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 1 day ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGIAX13.37N/A
N/A
Goldman Sachs Global Infras A
PAGLX45.92N/A
N/A
T. Rowe Price Global Growth Stock Adv
GVIRX17.96N/A
N/A
Goldman Sachs US Eq Div and Premium Inv
EQIIX13.51N/A
N/A
Allspring Emerging Markets Eq Advtg Inst
RSLAX61.66-0.38
-0.61%
American Funds SMALLCAP World R1

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with KRYS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
+4.55%
KRYS - ZLDPF
46%
Loosely correlated
-2.12%
CLDX - ZLDPF
30%
Poorly correlated
-2.72%
NERV - ZLDPF
22%
Poorly correlated
+8.50%
SNDX - ZLDPF
22%
Poorly correlated
-2.25%
MIST - ZLDPF
22%
Poorly correlated
-1.87%
More